Navidea Biopharmaceuticals, Inc. (NAVB)
NAVB Stock Price Chart
Explore Navidea Biopharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze NAVB price movements and trends.
NAVB Company Profile
Discover essential business fundamentals and corporate details for Navidea Biopharmaceuticals, Inc. (NAVB) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
10 Nov 1992
Employees
11.00
Website
https://www.navidea.comCEO
Craig A. Dais CPA
Description
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.
NAVB Financial Timeline
Browse a chronological timeline of Navidea Biopharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Earnings released on 4 Jun 2025
Earnings released on 29 May 2025
Earnings released on 28 Mar 2025
Earnings released on 18 Dec 2024
Earnings released on 27 Sept 2024
Earnings released on 27 Jun 2024
Earnings released on 19 Mar 2024
Earnings released on 14 Nov 2023
EPS came in at -$0.02 .
Earnings released on 11 Aug 2023
EPS came in at -$0.03 .
Earnings released on 11 May 2023
EPS came in at -$0.05 .
Earnings released on 21 Mar 2023
EPS came in at -$0.11 , while revenue for the quarter reached $610.00 , missing expectations by -98.78%.
Earnings released on 14 Nov 2022
EPS came in at -$0.25 , while revenue for the quarter reached $7.52K , missing expectations by -84.97%.
Earnings released on 15 Aug 2022
EPS came in at -$0.10 , while revenue for the quarter reached $6.52K , missing expectations by -86.96%.
Earnings released on 12 May 2022
EPS came in at -$0.10 .
Earnings released on 23 Mar 2022
EPS came in at -$0.12 falling short of the estimated -$0.03 by -300.00%, while revenue for the quarter reached $50.35K , missing expectations by -97.20%.
Earnings released on 10 Nov 2021
EPS came in at -$0.08 surpassing the estimated -$0.11 by +27.27%, while revenue for the quarter reached $96.38K , missing expectations by -83.94%.
Earnings released on 11 Aug 2021
EPS came in at -$0.09 matching the estimated -$0.09, while revenue for the quarter reached $261.05K , missing expectations by -56.49%.
Earnings released on 11 May 2021
EPS came in at -$0.11 falling short of the estimated -$0.08 by -37.50%, while revenue for the quarter reached $123.74K , beating expectations by +6.67%.
Earnings released on 24 Mar 2021
EPS came in at -$0.11 falling short of the estimated -$0.10 by -10.00%, while revenue for the quarter reached $219.25K .
Earnings released on 12 Nov 2020
EPS came in at -$0.13 falling short of the estimated -$0.08 by -62.50%, while revenue for the quarter reached $6.77K , missing expectations by -97.25%.
NAVB Stock Performance
Access detailed NAVB performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.